Medanta, Medicity announces 1st implant of 1st implantable cardioverter-defibrillator system to allow full-body MRI scans

Medanta announced it is one of the first to implant the Evera MRI SureScan implantable cardioverter-defibrillator (ICD) System, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The device was implanted by Dr Balbir Singh, Chairman- Department of Electrophysiology and Pacing Medanta, The Medicity, Gurgaon.

It is estimated that that as many as 63 per cent of ICD patients will need an MRI within 10 years of receiving a device. Until the availability of MR-Conditional ICD systems, patients with devices have been contraindicated from receiving MRI scans because of potential interactions between the MRI and device function.

“We are the first to make this latest technology available to patients. With this technology, in addition to having the highest standard in modern ICD treatment, patients implanted with an Evera MRI defibrillator will now have improved access to one of the most important diagnostic tools – the MRI. An ICD that allows patients to have full-body access to MRI is a significant breakthrough for this patient population. And at Medanta we believe in bringing the best technology to the people.” Said Dr Balbir Singh, Chairman- Department of Electrophysiology and Pacing Medanta, The Medicity, Gurgaon.

The Evera MRI features a contoured shape with thin, smooth edges that better fits inside the body, increasing patient comfort by reducing skin pressure by 30 per cent. The Evera MRI maintains the same industry-leading battery longevity (up to 11 years) compared to previous devices. In addition, Evera MRI is paired with the Sprint Quattro Secure family of ICD leads, which has 10 years of proven performance with active monitoring  and is safe for use in an MRI environment.

Evera MRI includes SmartShock 2.0 – an exclusive shock reduction algorithm that enables the device to better differentiate between dangerous and harmless heart rhythms. SmartShock technology helps to eliminate the inappropriate shocks, and delivers a 98-percent inappropriate shock free rate at one year. Also included in the Evera MRI is OptiVol 2.0 Fluid status monitoring and complete diagnostics, which helps to identify patients at risk of worsening heart failure and atrial fibrillation.

EH News Bureau